Certolizumab pegol in the treatment of Takayasu arteritis

Novikov P. I. , Smitienko I. O. , Sokolova M. V. , Alibaz-Oner F. , Kaymaz-Tahra S., Direskeneli H. , ...More

RHEUMATOLOGY, vol.57, no.12, pp.2101-2105, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 57 Issue: 12
  • Publication Date: 2018
  • Doi Number: 10.1093/rheumatology/key197
  • Title of Journal : RHEUMATOLOGY
  • Page Numbers: pp.2101-2105


Objectives. Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA).